$SILO News

Silo Pharma Agrees To Acquire Software And Related IP From Larry King, Issues 150,000 Shares In Consideration

Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting; To Buy Software And Intellectual Property From Norsight Consulting

Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder

Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting On August 18, 2026; Issues 165,000 Shares As Consideration For Asset Purchase

Silo Pharma Says Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Application Covering SPC-15, Intranasal 5-HT4 Receptor Agonist Targeting PTSD And Other Stress-Induced Psychiatric Disorders

Silo Pharma Says EPO Grants Patent Covering Preventative Approach Of Lead Candidate SPC-15, Intranasal, Nose-To-Brain Treatment Targeting PTSD And Stress-Induced Affective Disorders

Silo Pharma’s QwikAgents Engages AWS Premier Tier Services Partner Caylent To Design And Build AWS-Native QwikAgents Platform

Silo Pharma Shares Slide After Announcing Up to $11.7 Million Private Placement (SILO)

Silo Pharma’s QwikAgents Joins NVIDIA Developer Program To Enhance And Advance AI Agent Integration Platform

Silo Pharma Engages Drug-Device Development Partner Resyca To Carry Out Trial To Evaluate Nasal Spray System For Nose-To-Brain Delivery Of SPC-15 To Treat Post-Traumatic Stress Disorder

Silo Pharma Confirms Nine‑Month Stability Of SPC‑15 Intranasal Prophylactic, Supporting IND‑Enabling CMC Documentation.

SILO Pharma Q1 EPS $(0.12) Up From $(0.23) YoY, Sales $18.026K, Same YoY

Silo Pharma Launches Ibogaine-Based TBI Drug Initiative, Files Patent Amid Growing Psychedelic Therapy Push

Silo Pharma shares are trading lower after the company announced the acquisition of Qwikagents.ai.

Silo Pharma shares are trading lower after the company announced the acquisition of Qwikagents.ai.

Silo Pharma shares are trading lower after the company announced the acquisition of Qwikagents.ai.

Silo Pharma Expands Into Multi-Billion Dollar AI Agent Market with Acquisition Of Managed AI Agent Platform, Qwikagents.ai

Silo Pharma Highlights Pipeline Strength Amid Rising U.S. Policy Focus On Psychedelic Mental Health Treatments.

Silo Pharma Rallies After Securing Key Patent Allowance

Silo Pharma shares are trading higher after the company announced that the European Patent Office intends to grant a patent for an application titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress"